Search for: "Lisa Ouellette"
Results 141 - 160
of 173
Sorted by Relevance
|
Sort by Date
5 Nov 2021, 8:20 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
30 Jun 2021, 10:31 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
21 Apr 2020, 2:09 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
24 Jun 2020, 5:36 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
15 Apr 2020, 8:14 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
21 Jan 2022, 8:35 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe FDA has now authorized three vaccines and several treatments (including both monoclonal antibodies and small-molecule drugs) for the prevention and treatment of COVID-19. [read post]
8 Jun 2022, 5:23 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jul 2020, 12:12 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon horse named Jim was the United States’ most potent weapon against a raging diphtheria epidemic. [read post]
18 Jun 2020, 1:23 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
13 Aug 2020, 8:09 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about the importance of ensuring an adequate supply of diagnostic testing for COVID-19, and about the challenges the United States has faced so far on this front. [read post]
19 May 2020, 3:30 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
27 Sep 2021, 7:26 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsHistorically, the United States’ preparedness for a pandemic is like Charles Dudley Warner’s aphorism on the weather: everybody talks about it but no one ever does anything. [read post]
10 Jul 2020, 8:59 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development of a COVID-19 vaccine, which they view as critical to future management of the pandemic. [read post]
19 Aug 2020, 10:58 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
12 Jan 2021, 9:04 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
4 Mar 2021, 10:50 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or solution to—COVID-19 vaccine innovation problems? [read post]
30 Mar 2020, 8:40 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
5 Mar 2018, 10:43 am
On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages.** In other words, it could be true that IP-intensive… [read post]
5 Mar 2018, 10:43 am
On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages. [read post]
